Impact of oral antidiabetic agents on bone metabolism

Paul, Thomas; Nicolaï, Thomas

doi:10.4103/0971-5916.159244

Cited by 6 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the contrary, Asokan et al observed no association between HbA1c and BMD [ 6 ]. Many authors have noted that after a year of treatment, BMD decreased in the hip and spine, which may have been caused by the use of pioglitazone and insulin [ 53 , 54 , 55 ]. The use of pioglitazone is linked to the inability of mesenchymal stem cell precursors to commit to differentiating into osteoblast series [ 53 , 54 ].…”

Section: Discussionmentioning

confidence: 99%

Bone Mineral Density Evaluation Among Type 2 Diabetic Patients in Rural Haryana, India: An Analytical Cross-Sectional Study

Khandelwal,

Rajauria,

Kanjalkar

et al. 2023

Cureus

View full text Add to dashboard Cite

Background and objective Diabetes is one of the most prevalent diseases globally, affecting almost all organ systems. The relationship between type 2 diabetes mellitus (T2DM) and bone mineral density (BMD) has been a matter of controversy, and data from developing countries in this regard is highly scarce. Early detection of low BMD in diabetic patients will help prevent further bone loss and risk of fragility fracture. In this study, we aimed to assess the effect of T2DM on BMD among the rural population of Haryana, India. Materials and methods This was a cross-sectional study involving 850 patients between 25 and 60 years of age, including 425 diabetic and 425 non-diabetic subjects (as controls). Calcaneus BMD was measured by using quantitative ultrasound (QUS), and the data were compared against matched parameters in both groups. Results The mean age of diabetics was 42.21 ± 10.5 years and that of non-diabetics was 42.18 ± 10.4 years. The mean BMI was 27.8 ± 4.17 kg/m 2 in diabetics and 21.6 ± 3.32 kg/m 2 in the non-diabetic control group. BMD values significantly differed between the groups: -4.3 ± 1.23 vs. -2.6 ± 0.34 in diabetics and non-diabetics, respectively (p=0.002). Conclusion A significant difference in BMD was observed between the diabetic and non-diabetic groups. Based on our findings, We recommend that all type 2 diabetics be screened for osteoporosis so that this silent bone loss can be detected in the early phase itself and appropriate preventive measures can be promptly initiated.

show abstract

Section: Discussionmentioning

confidence: 99%

Bone Mineral Density Evaluation Among Type 2 Diabetic Patients in Rural Haryana, India: An Analytical Cross-Sectional Study

Khandelwal,

Rajauria,

Kanjalkar

et al. 2023

Cureus

View full text Add to dashboard Cite

show abstract

“…The mean of NTx (nM BCE/mM creatinine) of group1 was (29.6±7.8) is lower than that of group2 (44.6±6.1). There is a highly significant difference between the two groups in urinary NTx (P=0.000) Table 2 and 18] . An epidemiological analysis showed that 30.7% of healthy Saudi men, 50-79 years of age are osteoporotic [19] .…”

Section: Laboratory Measurementsmentioning

confidence: 94%

The Effect of Metformin on Markers of Bone Metabolism in Male Patients With Type 2 Diabetes Mellitus

Mohamed

Abdelgawad

Saber

et al. 2017

Zagazig University Medical Journal

View full text Add to dashboard Cite

Background: Bone is a vital, dynamic connective tissue that throughout life is continuously remodeled by balanced bone formation and resorption. It has been reported that diabetes and its metabolic disturbances and medications lead to important alterations in bone metabolism. The objective of this study is to determine the effect of metformin on markers of bone metabolism [Nterminal cross-linked telopeptide of type-1 collagen (NTx) and osteocalcin] in male patients with type 2 diabetes mellitus. Methods: a case-controlled study was conducted on 100 male type 2 diabetic patients. Their ages ranged from (35-50years) living in Saudi Arabia at Al-Madinah Al-Monawara Province. They were on oral antidiabetic drugs, divided into two groups according to treatment with metformin. Routine laboratory measurements included serum levels of fasting glucose, HbA1c, total calcium, inorganic phosphorus, total alkaline phosphatase and intact parathyroid hormone, osteocalcin was measured as a bone formation marker. Second-morning void urine was collected from patients to measure urinary NTx as a resorptive marker. Results: there was no significant difference between the two groups as regard the clinical, biochemical and diabetic control parameters(age, BMI, duration of diabetes, FBS, HbA1c, calcium, Phosphorus, total alkaline phosphatase, and iPTH). No statistical differences in osteocalcin (ng/ml) between the two groups (13.3±1.43 vs 13.0±1.4, P-value =0.348). The mean of NTx (nM BCE/mM creatinine) of metformin group 1 was (29.6±7.8) lower than that of non-metformin group 2 (44.6±6.1) with highly significant differences between the two groups (P=0.000).Conclusion: metformin may have a favorable effect on bone metabolism in type 2 diabetic males through a decrease of bone resorption marker, but more researches are required to know the overall impact of this medication on bone health on the long term.

show abstract

In vitro and in vivo investigation of PLA/PCL scaffold coated with metformin-loaded gelatin nanocarriers in regeneration of critical-sized bone defects

Shahrezaee

Salehi

Keshtkari

et al. 2018

Nanomedicine: Nanotechnology, Biology and Medicine

100

View full text Add to dashboard Cite

Impact of oral antidiabetic agents on bone metabolism

Cited by 6 publications

References 14 publications

Bone Mineral Density Evaluation Among Type 2 Diabetic Patients in Rural Haryana, India: An Analytical Cross-Sectional Study

Bone Mineral Density Evaluation Among Type 2 Diabetic Patients in Rural Haryana, India: An Analytical Cross-Sectional Study

The Effect of Metformin on Markers of Bone Metabolism in Male Patients With Type 2 Diabetes Mellitus

In vitro and in vivo investigation of PLA/PCL scaffold coated with metformin-loaded gelatin nanocarriers in regeneration of critical-sized bone defects

Contact Info

Product

Resources

About